Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after recovery from acute kidney injury feasibility trial
ACTRN12622001467729Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Feasibility of recruitment and retention and Feasibility based on protocol compliance. Started Nov 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12622001467729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001467729.